傳統(tǒng)動(dòng)物心電圖測(cè)量分析采用體表無(wú)創(chuàng)方式，雖操作簡(jiǎn)單，但是存在測(cè)量位置影響大、測(cè)量精度不高等局限性，而心外膜表面電極測(cè)量心電圖操作極為復(fù)雜且創(chuàng)傷性大，實(shí)驗(yàn)中較少采用。為解決這一難題，Scisence 提供微創(chuàng)的多電極電生理導(dǎo)管，獨(dú)特設(shè)計(jì)使研究者能夠?qū)ι镫娫谡麄€(gè)心臟的擴(kuò)散過(guò)程進(jìn)行更為深入的測(cè)量和分析。

電生理導(dǎo)管系統(tǒng)由八電極電生理導(dǎo)管、電極分配盒及第三方生物電放大器及刺激器組成。

工作原理：八電極電生理導(dǎo)管上的每對(duì)電極均受控于電極分配盒，電極分配盒通過(guò) 2mm 針式連接線與第三方生物電放大器或刺激器相連，通過(guò)生理記錄儀采集對(duì)應(yīng)的電極對(duì)引導(dǎo)的電信號(hào)數(shù)據(jù)。八電極電生理導(dǎo)管可用于心臟起搏，電信號(hào)記錄，進(jìn)而用于心臟電生理的各方面研究。

電生理導(dǎo)管系統(tǒng)特點(diǎn)

1. 微創(chuàng)八電極電生理導(dǎo)管，可監(jiān)測(cè)心內(nèi)各個(gè)部位的心電信號(hào)

2. 可同時(shí)引導(dǎo)心內(nèi) 4 個(gè)不同部位的心電信號(hào)，可觀察心電信號(hào)的擴(kuò)散過(guò)程

3. 同一根導(dǎo)管可同時(shí)用于采集信號(hào)和給予刺激

4. 小鼠 1.1F，電極間距 0.5mm；大鼠 1.9F，電極間距 1.0mm；導(dǎo)管電極間距可定制

5. 聚酰胺材料制作，生物相容性好，兼顧靈活性和剛性，光滑而便于插入

6. 電極分配盒控制每對(duì)電極，電極之間互不影響

7. 兼容多種第三方生物電放大器、刺激器、數(shù)據(jù)采集器，如美國(guó) iWorx 的 iWire-BIOx、IX-RA-834 等

8. 動(dòng)物實(shí)驗(yàn)用，不能用于人體

LabScribe 心電分析模塊

1. 測(cè)量心電圖 R-R、PR、QT、TP、QR、QTc 間隔，QRS、T、P 波寬，P、Q、R、S、T 波幅以及 ST段抬高等數(shù)據(jù)；

2. 具有具體的分析模板，可準(zhǔn)確描繪各波起點(diǎn)、波寬、波幅等；

3. 客戶可定制專門的 ECG 模板，以滿足自身特殊實(shí)驗(yàn)的需要；

4. 可從 R-R 間期、心率、噪音和活動(dòng)性等方面來(lái)劃定異常值，從而使分析更準(zhǔn)確。

5. 可輕松提取源數(shù)據(jù)或平均數(shù)據(jù)作為圖片或文本導(dǎo)出；

6. 可選 ASCII 文本導(dǎo)入模塊將其他第三方設(shè)備采集的 ECG 數(shù)據(jù)導(dǎo)入本軟件進(jìn)行分析；

LabScribe 進(jìn)行心電分析

相關(guān)文獻(xiàn)：

Luo X, et. al. “MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation.” J Clin Invest. 2013 May 1; 123(5): 1939-51

De Jong AM, et. al. “Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload.” PLoS One. 2013 Sep 6; 8(9): e72651

Guasch E, et. al. “Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model.” J Am Coll Cardiol. 2013 Jul 2;62(1):68-77

Cardin S, et. al. “Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure.” Circ Arrhythm Electrophysiol. 2012 Oct; 5(5): 1027-35

Iwasaki YK, et. al. “Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea.” Heart Rhythm. 2012 Sep; 9(9): 1409-16.e1

Jiao KL, et. al. “Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction.” J Cell Mol Med. 2012 Jun; 16(6): 1342-51

Zhou Y, et. al. “Matrine inhibits pacing induced atrial fibrillation by modulating I(KM3) and I(Ca-L).” Int J Biol Sci. 2012; 8(1): 150-8.

Benito B, et. al. “Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training.” Circulation. 2011 Jan 4; 123(1): 13-22

Prestia KA, et al. “Increased Cell-Cell Coupling Increases Infarct Size and Does not Decrease Incidence of Ventricular Tachycardia in Mice.” Front Physiol. 2011 Jan 31; 2(1): 1-7

Aubin MC, et al. “A high-fat diet increases risk of ventricular arrhythmia in female rats: enhanced arrhythmic risk in the absence of obesity or hyperlipidemia.” J Appl Physiol. 2010 Feb; 108: 933-940

Lu Y, et al. “MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation.” Circulation. 2010 Dec; 122(23): 2378-87

Mathur N, et al. “Sudden infant death syndrome in mice with an inherited mutation in RyR2.” Circ Arrhythm Electrophysiol. 2009 Dec; 2: 677-685